Deficiencies and Substitution of Testosterone

#### **Chapter 5**

## Lung Health and Hypoandrogenism

*Nidia N. Gomez, Verónica S. Biaggio, Eloy Salinas, Silvana N. Piguillem, María Eugenia Ciminari, María Verónica Pérez Chaca and Silvina Mónica Álvarez*

#### **Abstract**

Epidemiological reports offer evidence that gender differences mediate respiratory diseases. Male sex is a major risk factor for respiratory distress syndrome and bronchopulmonary dysplasia in neonates. An imbalance between oxidants/antioxidants leads to stress, which has been implicated in airway disease development. It is known that androgens deficiency induces oxidative stress and lipid peroxidation in the lung, synchronically with changes in the expression of cytoprotective markers. Additionally, males are more susceptible to acute and chronic inflammation after toxicant exposure. Besides, nutrition is an important factor, given that lipids are the main blocks for surfactant production and for testosterone synthesis. Also, an adequate amount of Zn in the diet prevents inflammation and is necessary for testosterone and androgen receptor structure and function. This chapter focuses on understanding the effect and clinical implications of testosterone deficiency on lung tissue as well as exploring the role of lipids and zinc in the outcome of several respiratory diseases.

**Keywords:** androgens, lung, male, inflammation, respiratory diseases

#### **1. Introduction**

#### **1.1 Lung structure and sex differences**

Biological sex mediates differences in lung disease incidence and pathophysiology, which emerge from sex variations in lung structure and function itself and also in the lung immune cells that are recruited during inflammation [1]. In healthy women, large conducting airways are 30% smaller than in healthy men and sex variations in the airway luminal area persist even after matching for lung size. Larger conducting airways are the main site of airway resistance, linking anatomy to analyzed sex differences in pulmonary physiology [2]. The female lung during intrauterine development has several structural advantages over the male lung. Even if surfactant is produced earlier, the female lung is smaller whereas it has a larger amount of alveoli per unit area. Lung maturation, therefore, is faster in females than in male fetuses. Also, neonatal females have higher expiratory flow rates than males. Regarding respiratory distress syndrome development, bronchopulmonary dysplasia in neonates, and asthma, males present superior risk factors than women during childhood [3].

In this chapter, we also review sex differences in the structure and function of healthy lungs as well as lungs in pathological conditions that depend on the sex hormones' action. Testosterone deficiency (TD) is very common in older men and is related to different signs and symptoms, such as diminished libido, reduced sexual function, and decreased mobility and energy; which could greatly affect the aging process and quality of life [4, 5]. Androgen receptor (AR) is the intermediary of testosterone effects which is subjected to its sensitivity [6].

Several studies support interdependent sex and endogenous sex hormones effects on lung growth and airways responsiveness that might explain asthma status from puberty to middle age. Puberty is a dynamic process regulated by hormonal signals from the central nervous system that results in sexual maturation. Assessment of the pubertal stage development is different in boys from girls. In boys, androgen production gradually increases both from the testes producing testosterone and from the adrenal glands producing weaker androgens—ultimately leading to puberty. Girls experience increases in estrogen production from the ovaries (driving thelarche and ultimately menarche) and androgens such as androstenedione and DHEA-S from the adrenal glands (driving puberty). In children, pubertal maturation and asthma status may also be affected by corticosteroid treatments [7]. Androgen surge during puberty is capable of conferring protective influences on lung growth in both males and females whereas estrogens could well have deleterious effects in females extending into adult development.

#### **2. Androgen receptor**

The androgen receptor (AR) belongs to the steroid and nuclear receptor superfamily. Among this large family of proteins, only five vertebrate steroid receptors are known: androgen, estrogen, progesterone, glucocorticoid, and mineralocorticoid receptors [8–10]. Two subtypes of estrogen receptors have been identified: α and β. Like other steroid receptors, AR is a soluble protein that operates as an intracellular transcriptional factor. AR function is regulated by androgen binding, which initiates sequential conformational receptor changes that affect both receptor-protein and DNA interactions. AR-regulated gene expression is reliable for male sexual differentiation and pubertal changes. The known AR ligands can be classified as steroidal or non-steroidal based on their structure either as agonist or antagonist, based on their ability to activate or inhibit target genes' transcription [8, 9]. AR is mainly expressed in androgen target tissues, such as the prostate, skeletal muscle, liver, lung, and central nervous system (CNS). The highest expression levels are observed in the prostate, adrenal gland, and epididymis as determined by real-time polymerase chain reaction (PCR). AR can be activated by endogenous androgens merging, including testosterone and 5R-dihydrotestosterone (5R-DHT).

Physiologically, functional AR is reliable for male sexual distinction in the uterus and for male pubertal changes. In adult males, androgen is mainly responsible for maintaining libido, spermatogenesis, muscle mass and force, bone mineral density, and also erythropoiesis. Androgens are regularly dispersed all over the entire organism, especially in the lungs.

#### **3. Immune system**

Many immune cells in the lungs express ARs and are susceptible to androgens, like ARs on myeloid immune cells (monocytes and macrophages) as they are associated

#### *Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

with healthiness and illness. Particularly, we point out androgen influences on lung diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and lung fibrosis.

Immune response differs between males and females because its type and magnitude are influenced by biological sex and age. Genetic (chromosomal) sex differences and those mediated by the action of sex hormones engendered sex differences in the immune system function. Female hormones, mainly estrogens, have been well studied in their numerous functions, while androgen as modulators of the immune system has not been investigated so extensively [8, 9].

Myeloid cell response in the lung is modulated by androgens, which results in the outcome of different lung diseases. Incidence and pathophysiology of lung diseases are mediated by biological sex. These variations emerge from sex differences in the lung structure and function, and also in the immune cells that populate the lung and are recruited to it during inflammation. Before birth, the female lung has several structural advantages over the male lung, as stated in the first paragraph.

Despite lung contribution to structural dissimilarities between the sexes, those differences in lung function and diseases are also influenced by sex hormones. Testosterone and estrogen affect lung macrophage functions [11]; therefore, this may contribute to particular lung disease development. The amount of AR cellular expression and hormone concentration regulates testosterone's immunoregulatory characteristics.

In fact, when we refer to the physiological function of the lung, alveolar macrophages (AM) are the most abundant cell type of the immune system and one of the first cells in contact with the allergenic stimulus. During the inflammatory process, Th2 immune response polarizes AM to an M2 phenotype [12] and the accumulation of M2-polarized AM in the lung correlates with asthma severity [13]. AM (M2) secretes cytokines that recruit eosinophils during allergic lung inflammation [14].

Keselman et al. [15] analyzed the effect of estrogen on macrophage polarization, suggesting an enhanced M2 polarization, which indicates a long-lasting effect on lung inflammation. On the other side, Becerra Diaz et al. [11] evaluated the role of androgens in lung inflammation, particularly AM polarization in allergic lung inflammation, finding out that AM1 expression was restored to control values with androgen-replacement therapy. Both experiments contribute to explaining the sex differences observed in asthma.

#### **4. Surfactant**

Pneumocytes are alveolar cells found on the alveoli surface in the lungs. There are two types of cells that cover the alveoli: type I and type II pneumocytes (PTI and PTII, respectively). They are present in a ratio of 1:2. PTI cells form the majority of the epithelium while PTII cells account for only about 15% of peripheral lung cells [16]. Type I pneumocytes are thin squamous cells that cover almost 95% of the alveolar surface. Pneumocytes are connected to each other by tight junctions. The adjacent PTI cells are connected by tight or occluding junctions that prevent leakage of fluid into the alveolar space. During inspiration and expiration, the flat extensions overlap each other. The type I cells are involved in the gaseous exchange between the alveoli and capillaries.

Type II pneumocytes are cubic in shape and they are characterized by microvilli on their surface. The major functions of the type II cells include the secretion of

surfactant to reduce surface tension. PTII can convert into PTI cells and regenerate the alveolar surface at the time of injury. The coating of these lipids in alveoli is relevant, without which the alveoli may collapse. The surfactant is secreted by secretory granules called lamellar bodies. These tension active are made up of 70–80% of phospholipids and small proteins called surfactant proteins (sp). Surfactant proteins start to be secreted at about 25 weeks of gestation.

Surfactant is produced in fetal life, and, glucocorticoid receptor (GR) is essential in promoting differentiation and maturation of PTII cells during embryonic life [9, 10, 17]. Antenatal glucocorticoid administration accelerates lung maturation in infants at risk of preterm delivery, largely through increased surfactant protein expression.

Ojeda et al. have shown that testosterone absence alters surfactant phospholipid composition, mainly increasing phosphatidylcholine content [18], and leading to damage in the lung parenchyma. Thus, the male sex is a major risk factor for the development of respiratory distress syndrome, bronchopulmonary dysplasia in neonates [9, 10, 17, 18], and asthma in childhood [9, 17]. Androgen receptor (AR) mediates the effects of male sex steroids in a variety of reproductive and non-reproductive tissues both in males and females under physiological and pathophysiological conditions [9, 10, 17, 18].

#### **5. Androgen deficiency and oxidative stress**

It is known that redox balance is important in the airways because it is the first contact with environmental contaminants, particles, cigarette smoke (CS), and pathogens.

Chemically, oxidation is a reaction where a substance loses electrons and is oxidized, which can occur by mechanisms that enhance the production of free radicals (unstable substances with unpaired electrons), developing chain reactions. These reactions are uncontrollable as long as they have sufficient substrate to continue developing and can cause damage to the different components of the cells, especially those of a lipid nature. Antioxidants end the reaction by interacting with intermediate compounds and preventing their spread [19].

Therefore, an imbalance between oxidants/antioxidants induces stress, which has been implicated in the development of airway diseases. Several antioxidant enzymes are critical for maintaining cellular homeostasis and preventing cellular damage [20].

Oxidative stress causes an imbalance in the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and their relationship with the antioxidant defense system of lung cells [21]. Some ROS and RNS responsible for oxidative stress such as superoxide, ozone, hydrogen peroxide, hydroxyl radical, nitrate, nitrosyl, and nitrosothiol [22] are produced as by-products of metabolic processes in cells [23] and play a vital role in regulating various biological phenomena, some of which are associated with proinflammatory processes [24].

ROS have a dual involvement in the cell, taking part in different cellular functions, such as defense against infectious agents and signaling systems. On the contrary, its accumulation in biological systems produces oxidative stress, representing an alteration in the pro-oxidant/antioxidant balance, with the ability to oxidize biomolecules (lipids, proteins, DNA), and inhibit their normal structure and function.

One of the indicators of oxidative damage in the lung is lipid peroxidation which causes a considerable amount of DNA-malondialdehyde (MDA) adducts [25]. Lipid

#### *Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

peroxidation affects all cell membranes inducing numerous injuries and loss of functions. On the other hand, ferroptosis is a form of cell death characterized by iron-dependent lipid peroxidation, which induces cell death. During ferroptosis, an accumulation of polyunsaturated fatty acids (PUFAs) occurs. This involves PUFAdriven lipid peroxidation that increases cell membrane permeability making the cell more sensitive to oxidation [26]. Enzymatic antioxidants and non-enzymatic antioxidants act together to detoxify the effects of oxidative stress and lipid peroxidation. This synergistic action can be measured using total antioxidant capacity (TAC) [27].

Additionally, males are susceptible to acute neutrophilic inflammation after a single exposure to toxicants, as well as chronic monocytic inflammation after repeated exposures to them. Exposure to ozone has numerous negative effects on lung health and innate pulmonary host defense. Sex differences in lung histology and BAL measurements of lung injury and inflammation were found. Females showed increased damage compared to males, and the expression of inflammatory mediators also varied with sex under basal conditions and following exposure to ozone. This situation indicated a potential sexual dimorphism in the mechanisms associated with the inflammatory response to this air pollutant. Understanding how differentially expressed genes regulate the response to environmental insults may provide the bases to identify sex-specific targets for therapy against acute lung inflammation and injury [28].

There is abundant evidence revealing the action of heat shock proteins (HSPs), mainly in inflammatory conditions. At 30 days after castration, we have shown [20] an increase in oxidative stress markers such as TBARS and antioxidant enzymes expression such as glutathione peroxidase (GPx). During the period of testosterone supplementation, the expression of cytoprotective markers as HSP70i increased, compared to the control group. Additionally, we have observed a decreased HSP27 expression in the testosterone-deprived group. This situation suggests an absence or decrease in cytoprotective properties, which would correlate with the increased level of TBARS found in the lung.

On the other hand, it has been found that a higher expression of Hsp70 reduces the production of nitric oxide (NO) [29], so the higher immunostaining of HSP70 would explain the absence of variations in the concentration of NO in BAL of castrated rats. Therefore, the expression of these proteins would probably play a protective role against androgen deficiency [20].

Besides, sexual hormones play an important role in airway-related diseases and the immune response, leading to pulmonary injuries [30]. Several studies have shown that sex hormones can affect airway tone and inflammation, and exert effects on different lung cell types, including airway smooth muscle [31] and immune cells. These include lung macrophages, neutrophils, dendritic cells, and eosinophils [32, 33].

Testosterone deficiency is commonly observed in male patients with COPD, which is characterized by chronic inflammation of the airways and pulmonary emphysema [34]. As it was previously mentioned, testosterone affects lung macrophage function and this may contribute to the outcome of particular lung diseases. Low levels of endogenous testosterone have been found in men suffering from pathologies such as asthma, COPD, or tuberculosis.

In experimental situations, when testosterone was administered in castrated rats, oxidative stress parameters were modified. For example, TBARS, catalase (CAT), and GPx activities went back to normal values. The same happened with NADPH oxidase (NOX) and GPx expression which were increased in castrated rats and showed a decrease to control values in rats supplemented with testosterone [20, 35].

Epigenetic events cause hyper-methylation (via the promoter) of GSTP1 and Nrf2, which reduces their expression and severely decreases cellular antioxidant capacity. The excessive production of ROS, due to metabolic alterations, and/or extrinsic environmental factors such as pulmonary inflammation along with androgen receptor activation favor oxidative stress state [36]. It is important to highlight that oxidative stress can modify the activity of nuclear and mitochondrial DNA, generating hypermethylation and mutations [24].

COPD is associated with an abnormal inflammatory response of the airways, alveoli, and microvasculature. Testosterone deficiency also exacerbates COPD symptoms through direct impact on respiratory muscles or decrease exercise capacity. The main cause of the inflammatory process is cigarette smoke [37]. The inflammatory response in COPD progression involves both innate and adaptive immunity [38], which are mediated by multiple immune cell types, including macrophages, T cells, B cells, and neutrophils, as well as epithelial cells [39]. The insufficient control of inflammatory responses to tissue damaging in COPD may be liked to low testosterone.

Overactive tissue and wound healing responses dysregulation in the lung could be used to describe the Th2 response in allergic asthma [3]. Allergic asthma is a chronic disease, which occurs with an altered inflammatory immune response. In the alveolar space of normal lungs, alveolar macrophages are the most abundant immune cells and are the first to come into contact with allergic stimuli. In allergic asthma, Th2 polarizes AM to the M2 phenotype, and the increase of this phenotype is directly related to the severity of pathology. Androgens increase the polarization of AM to M2, although they suppress all other effects of allergic inflammation. These results underscore a little-known role of androgens as modulators of the immune response [3].

Airway epithelial cells are activated to produce inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), granulocyte-macrophage colony-stimulating factor, interleukin-8 (IL-8), and interleukin-6 (IL-6). Nuclear factor kβ (NF-kβ) is crucial for inflammatory pathologies, regulating the transcription of the cytokines TNF-α, IL-1b, and IL-6 [40]. Moreover, androgen deficiency increases inflammation by increasing levels of IL-6, TNF-α, and C-reactive protein [40, 41]. Wang and colleagues [40] found that male castration increased both inflammatory cell recruitment and TNF-α and IL-6 expression. Similar results were found in clinical reports, where higher levels of IL-6, IL-1b, and TNF-α in men with low testosterone levels (hypogonadism) were found [40–42].

In many cases, impaired testicular function and subfertility are associated with obesity, which is a chronic disease associated with metabolic disorders and comorbidity. In this situation, the production of ROS and the release of hormones can affect the hypothalamus-pituitary-testicle axis. Androgen deficiency could further accelerate the increase in adipose tissue and induce a vicious cycle. In individuals where adipose tissue dysfunction and male hypogonadism occur together, a multifactorial pathology of difficult resolution are produced at the pulmonary level [42].

#### **6. Zn deficiency and testosterone**

In 1992, Hunt et al. showed that Zn depletion induced a decrease in serum testosterone concentrations in men. Hamdi et al. (1997) also showed a direct action of Zn on testicular steroidogenesis, supporting the idea that Zn deficiency induced hypogonadism mainly from changes in testicular steroidogenesis or indirectly from Leydig cell failure [43, 44].

#### *Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

Omu et al. [45] proved Zn deficiency to be associated with impaired spermatogenesis due to reduced testosterone production, increased oxidative stress, and apoptosis. They showed an obvious reduction of testicular volume, together with increased apoptosis of the testicular cell population. It is known that the zinc transporter (ZnT) family, SLC30a, is involved in the maintenance of Zn homeostasis and in mediating intracellular signaling events.

Zn deficiency has been demonstrated to cause Leydig cells to appear smaller and show endoplasmic reticulum abnormalities when examined under an electron microscope [46, 47]. Chu et al. [48] showed that Zn-deficient (ZnD) Leydig cells were capable of taking up cholesterol and neutral lipids, which are the precursors of sex steroids; however, they could not convert them into sex steroids, thus leading to fertilization impairment due to spermatogenesis arrest.

Two Zn-transporter families regulate Zn homeostasis: Zrt- and Irt-like proteins (ZIPs; SLC39a) and another Zn transporter (ZnT) proteins (SLC30a). ZIPs are responsible for the influx of Zn into the cytoplasm from the cell exterior or from intracellular compartments whereas ZnTs are responsible for Zn efflux to the cells outside or to intracellular organelles [48].

Chu et al. [48] were the first to demonstrate that Znt7 is involved in testosterone synthesis in the mouse testis. The mechanism underlying this process may involve the modulation of the expression levels of testosterone-related factors as well as the expression of the enzymes involved in testosterone synthesis.

On the other hand, according to the crystal structure of the AR DNA binding domain (DBD), each DBD monomer has a core composed of two zinc fingers, each of which consists of four cysteine residues that coordinate a zinc ion. AR, just like other steroid receptors, works as a dimer that binds to the respective response element in the DNA promoter consisting of two equal sites: hexamers sites (5′-AGAACA-3′) separated by a 3 base-pair spacer (IR3). Therefore, this could be another site that could be affected by Zn deficiency, leading to different diseases or deficiencies [49].

Furthermore, in our laboratory we have studied the effect of Zn deficiency in the lung, finding that it induces nitrosative and oxidative stress together with inflammation and alteration in the expression of matrix extracellular proteins [50]. It also increases the expression of apoptosis markers such as Bax and Bad, suggesting that together with the reduced levels of testosterone induced by the same Zn deficiency, the impact on the lung and the risk for chronic and aggressive diseases could be much higher.

#### **7. COVID and testosterone**

It has been shown that male individuals are more susceptible to the infection of SARS-CoV-2 than females, and have a higher death rate regardless of age [51].

The explanation for this finding could be: (a) androgens per se are poorly protective over the immune response in males, whereas estrogens (and progesterone) can provide adequate protection to females, stimulating the humoral response to viral infections [52] as a consequence, T levels could not elicit an effective counteracting response to the inflammatory and immunological outcome resulting from a viral infection; (b) a background condition of chronic low T levels—which is estimated to characterize up to 20% of middle-aged/elderly men—may facilitate overall greater incidence and higher severity in men compared to women; and (c) SARS-CoV-2 needs androgen-regulated proteins to invade host cells, including TMPRSS2 for S priming and ACE2 for viral entry, which is expressed in multiple tissues [53].

#### **8. Lung cancer**

Lung cancer is the most diagnosed cancer worldwide. Sex hormone concentrations decline as men age, together with increased cancer incidence. For instance, T, DHT, and estrogen (E) were measured in community-dwelling older men and the results revealed that higher levels of androgen were associated with elevated frequency of lung cancer, while they are not associated with the incidence of prostate and colorectal cancer [58]. Therefore, sex hormones may play a role in lung cancer pathophysiology and patient development even if it is not considered as a hormone-sensitive malignancy. An interesting study performed in Canada [59], using a retrospective cohort design, provides further evidence that sex hormones may play a role in lung cancer pathophysiology, and that androgens in particular may have a greater role than previously thought. Male patients, after they were diagnosed with lung cancer, were exposed to androgen pathway manipulation (APM) where most of them received 5-alpha reductase inhibitors and they significantly had better survival when compared to the not exposed ones. Thus, APM utilization in specific lung cancer populations has the potential to be a simple, widely available, and cost-effective treatment for this disease.

It is important to remember that there are two types of lung cancer, non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma, which correspond to 85 and 15% of all lung cancer, respectively. Regarding NSCLC, it is classified into three types: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma [54]. The most common is adenocarcinoma that arises from small epithelial type II alveolar cells that produce mucus among other substances [55]. It usually occurs in the lung periphery. When compared to other lung cancers, adenocarcinoma is a slow grower and is usually found before spreading outside the lungs. Squamous-cell carcinoma emerges from early versions of squamous cells from airway epithelial cells in the bronchial tubes in the lungs center.

Large cell carcinoma accounts for 5–10% of lung cancers. This cancer does not show evidence of squamous or glandular maturation therefore it is usually diagnosed by default, excluding other possibilities. It often begins in the central part of the lungs, nearby lymph nodes and into the chest wall [56]. This kind of cancer and tumors are strongly associated with smoking [57].

Female patients generally show better survival rates at any stage of the disease. Histological subtypes of the disease in women include proportionally more adenocarcinoma and less squamous cell carcinoma than in men. Apparently, men have a higher rate of fatal outcomes in lung cancer, but surprisingly, they tend to be less vulnerable to tobacco than women.

#### **9. The analysis of biomarkers**

Nowadays, novel therapeutic approaches for the management or monitoring of different lung illnesses are needed. The use of biomarkers and the measurement of their levels as a control for the risk and disease prognosis are considered an encouraging approach. Many types of biomarkers have been identified, which include blood protein biomarkers, cellular biomarkers, and protease enzymes. They have been isolated from different biological sources including sputum, bronchoalveolar fluid, exhaled air, and blood. Sputum samples from patients have been proposed as easily obtained samples that allow complementary diagnostic techniques or alternatives to PCR.

*Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

By real-time PCR, reactive oxygen species can be diagnosed from fresh sputum. ROS in sputum could be employed to monitor patients with pathologies such as asthma and COPD. Other modern bioanalytical techniques detect levels of ROS and were used during the COVID-19 pandemic to show oxidative status, at all times [58–61].

Also, higher plasma androgens, particularly DHT, would represent a potential biomarker for lung cancer incidence in older men.

#### **10. Conclusion**

We have shown that considerable advances have been made in the understanding of the pathophysiology of lung diseases. It is obvious that the absence of androgens

#### **Figure 1.**

*The different cell functions altered by testosterone deficiency (A). There is an increase in oxidative stress due mainly to a decreased function of antioxidant enzymes. Nitrosative stress is also increased, due to the increased production of NO by iNOS. Inflammation under testosterone deficiency induces a Th1 response. This also induces a decrease in cytoprotective markers, ending in increased apoptosis. Taking together all these effects induces severe histological damage in the lung, making it weaker and more susceptible to diseases, which could end up in COPD, severe prognosis in COVID-19; lung cancer, asthma, and tuberculosis. The histological damage induced by the absence of testosterone after 1 month of treatment (B). (1) Control rat lung. The lung tissue appears normal and the alveoli are homogeneously distributed. The interalveolar septa show typical development of the normal lung. (2) Surgically castrated rat lung. The pulmonary parenchyma presents numerous large spaces caused by the rupture of the interalveolar septa. In other regions, the fibrous connective tissue has increased.*

induces oxidative stress and lipid peroxidation in the lung, together with changes in the expression of cytoprotective markers, leading to important alterations in the histoarchitecture of this organ (**Figure 1**). This would lead to a weaker lung, susceptible to undergo several respiratory diseases.

The fact that testosterone levels decrease in elderly men explains the high prevalence of these diseases when compared to women of the same age. All these should be considered to better understand the etiology of respiratory diseases and propose therapies for these patients.

### **Author details**

Nidia N. Gomez1,2\*, Verónica S. Biaggio1,2, Eloy Salinas3 , Silvana N. Piguillem1 , María Eugenia Ciminari1 , María Verónica Pérez Chaca1 and Silvina Mónica Álvarez1,2

1 Faculty of Chemistry, Department of Biochemistry, Biochemistry and Pharmacy, National University of San Luis, San Luis, Argentina

2 IMIBIO-CONICET, San Luis, Argentina

3 Faculty of Chemistry, Department of Biological Sciences, Biochemistry and Pharmacy, National University of San Luis, San Luis, Argentina

\*Address all correspondence to: gomez.nidia@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### **References**

[1] Sellau J, Groneberg M, Lotter H. Androgen-dependent immune modulation in parasitic infection. Seminars in Immunopathology. 2019;**41**:213-224. DOI: 10.1007/ s00281-018-0722-9

[2] Dominelli PB, Ripoll JG, Cross TJ, Baker SE, Wiggins CHC, Welch BT, et al. Sex differences in large conducting airway anatomy. Journal of Applied Physiology. 2018;**125**:960-965. DOI: 10.1152/japplphysiol.00440.2018

[3] Becerra-Diaz M, Song M, Heller N. Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung. Frontiers in Immunology. 2020;**11**:1698. DOI: 10.3389/fimmu.2020.01698

[4] Baum MJ. Sexual differentiation of pheromone processing: Links to male-typical mating behavior and partner preference. Hormones and Behavior, 2009 55: 579-588. https://doi. org/10.1016/j.yhbeh.2009.02.008

[5] Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Therapeutic Advances in Urology. 2016;**8**(2):147-160. DOI: 10.1177/ 1756287215617648

[6] Simanainen U, Brogley M, Gao YR, Jimenez M, Harwood DT, Handelsman DJ, et al. Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. Molecular and Cellular Endocrinology. 2011;**342**(1-2):81-86. DOI: 10.1016/j.mce.2011.05.011

[7] Zein JG, McManus JM, Sharifi N, Erzurum SC, Marozkina N, Lahm T, et al. Benefits of airway androgen

receptor expression in human asthma. American Journal of Respiratory and Critical Care Medicine. 2021;**204**(3):285- 293. DOI: 10.1164/rccm.202009-3720OC

[8] Levin ER. Integration of the extra-nuclear and nuclear actions of estrogen. Molecular Endocrinology. 2005;**19**:1951-1959

[9] Stabile L, Davis A, Gubish C, Hopkins T, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor and show biological responses to estrogen. Cancer Research. 2002;**62**:2141-2150

[10] Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. The Journal of Biological Chemistry. 2007;**282**:22278-22288

[11] Becerra-Díaz M, Strickland AB, Keselman A, Heller NM. Androgen and androgen receptor as enhancers of M2 macrophage polarization in allergic lung inflammation. Journal of Immunology. 2018;**201**(10):2923-2933. DOI: 10.4049/ jimmunol.1800352

[12] Boorsma CE, Draijer C, Melgert BN. Macrophage heterogeneity in respiratory diseases. Mediators of Inflammation. 2013;**2013**:769214. DOI: 10.1155/ 2013/769214

[13] Nikonova A, Khaitov M, Jackson DJ, Traub S, Trujillo-Torralbo MB, Kudlay DA, et al. M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. eBioMedicine.

2020;**54**:102734. DOI: 10.1016/j. ebiom.2020.102734

[14] Ford AQ, Dasgupta P, Mikhailenko I, Smith EM, Noben-Trauth N, Keegan AD. Adoptive transfer of IL-4Rα+ macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunology. 2012;**13**:6. DOI: 10.1186/1471-2172-13-6

[15] Keselman A, Fang X, White PB, Heller NM. Estrogen signaling contributes to sex differences in macrophage polarization during asthma. Journal of Immunology. 2017;**199**(5):1573-1583. DOI: 10.4049/ jimmunol.1601975

[16] Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. Allometric relationships of cell numbers and size in the mammalian lung. American Journal of Respiratory Cell and Molecular Biology. 1992;**6**:235-243

[17] Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell. 2001;**104**:719-730

[18] Ojeda MS, Gómez NN, Gil E, Scardapane L, Gimenez MS. Morphologic and biochemical changes in castrated rat lung after surgical and pharmacological castration. Brazilian Journal of Medical and Biological Research. 2000;**33**:279-285

[19] Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: Properties, sources, targets, and their implication in various diseases. Indian Journal of Clinical Biochemistry. 2015;**30**(1):11-26. DOI: 10.1007/s12291-014-0446-0

[20] Alvarez SM, Biaggio VS, Ciminari ME, Piguillem SN, Pacheco Guiñazú AB, Escobar Correas SM, et al. Androgen deprivation and cytoprotective parameters in rat lung. International Journal of Research Studies in Biosciences (IJRSB). 2015;**3**:150-163

[21] Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiological Reviews. 2014;**94**:329-354. DOI: 10.1152/physrev.00040.2012

[22] Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, et al. Oxidative stress, prooxidants, and antioxidants: The interplay. BioMed Research International. 2014;**2014**:761264. DOI: 10.1155/2014/761264

[23] Di Meo S, Reed TT, Venditti P, Victor VM. Role of ROS and RNS sources in physiological and pathological conditions. Oxidative Medicine and Cellular Longevity. 2016;**2016**:1245049. DOI: 10.1155/2016/1245049

[24] Bassey IE, Emodi BA, Akpan UO, Iyakndue IFA, Anakebe EA, Icha BE, et al. Impact of androgen deprivation on oxidative stress and antioxidant status in Nigerian patients with prostate cancer undergoing androgen deprivation therapy. JCO Global Oncology. 2020;**6**:1481-1489. DOI: 10.1200/ GO.20.00290

[25] Bassey IE, Ikpi DE, Isong IKP, Akpan UO, Onyeukwu CC, Nwankwo NP, et al. Effect of combined calcium, magnesium, vitamin C and E supplementation on seminal parameters and serum oxidative stress markers in fructose-induced diabetic Wistar rats. Archives of Physiology and Biochemistry. 2020;**25**:1-8. DOI: 10.1080/13813455. 2020.1716017

*Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

[26] Ye Z, Liu W, Zhuo Q, Hu Q, Liu M, Sun Q, et al. Ferroptosis: Final destination for cancer? Cell Proliferation. 2020;**53**(3):e12761

[27] Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxidative Medicine and Cellular Longevity. 2016;**2016**:3164734. DOI: 10.1155/ 2016/3164734

[28] Cabello N, Mishra V, Sinha U, DiAngelo SL, Chroneos ZC, Ekpa NA, et al. Sex differences in the expression of lung inflammatory mediators in response to ozone. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2015;**309**:L1150-L1163. DOI: 10.1152/ajplung.00018.2015

[29] Hu C, Yang J, Qi Z, Wu H, Wang B, Zou F, et al. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. MedComm (2020). 2022;**3**(3):e161. DOI: 10.1002/mco2.161

[30] Voltz JW, Card JW, Carey MA, Degraff LM, Ferguson CD, Flake GP, et al. Male sex hormones exacerbate lung function impairment after bleomycininduced pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology. 2008;**39**(1):45-52. DOI: 10.1165/ rcmb.2007-0340OC

[31] Prakash YS. Emerging concepts in smooth muscle contributions to airway structure and function: Implications for health and disease. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2016;**311**:L1113-L1140. DOI: 10.1152/ajplung.00370.2016

[32] Keselman A, Heller N. Estrogen signalling modulates allergic

inflammation and contributes to sex differences in asthma. Frontiers in Immunology. 2015;**6**:568. DOI: 10.3389/ fimmu.2015.00568

[33] Leffler J, Stumbles PA, Strickland DH. Immunological processes driving IgE sensitisation and disease development in males and females. International Journal of Molecular Sciences. 2018;**19**(6):E1554. DOI: 10.3390/ijms19061554

[34] Tamaki K, Sakihara E, Miyata H, Hirahara N, Kirichek O, Tawara R, et al. Utility of self-administered questionnaires for identifying individuals at risk of COPD in Japan: The OCEAN (Okinawa COPD case finding Assessment) study. International Journal of Chronic Obstructive Pulmonary Disease. 2021;**16**:1771-1782. DOI: 10.2147/ COPD.S302259

[35] Ciminari ME, Pérez Chaca MV, Álvarez SM, Biaggio VS, Gómez NN. Analysis of the relationship between zinc deficiency, androgen disorders, and lung. In: Preedy V, Patel V, editors. Handbook of Famine, Starvation, and Nutrient Deprivation. Cham: Springer. pp 1931-1950. DOI: 10.1007/978-3-319-55387-0\_90

[36] Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH. Oxidative stress in prostate cancer: Changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer and Prostatic Diseases. 2013;**16**:217-225. DOI: 10.1038/pcan.2013.13

[37] Rabe KF, Watz H, Baraldo S, Pedersen F, Biondini D, Bagul N, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): A 16-week, randomised, placebo-controlled trial. Lancet. 2018, 2018;**389**:1931-1940. DOI: 10.1016/ S2213-2600(18)30331-X

[38] Kotlyarov S. Involvement of the Innate Immune System in the Pathogenesis of Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences. 2022;**23**(2):985. DOI: 10.3390/ ijms23020985

[39] Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. American Journal of Respiratory and Critical Care Medicine. 2001;**164**(3):469-473. DOI: 10.1164/ajrccm.164.3.2007149

[40] Wang X, Huang L, Jiang S, Cheng K, Wang D, Luo Q, et al. Testosterone attenuates pulmonary epithelial inflammation in male rats of COPD model through preventing NRF1 derived NF-kB signaling. Journal of Molecular Cell Biology. 2021;**13**(2):128- 140. DOI: 10.1093/jmcb/mjaa079

[41] Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: A nested cross-sectional study. PLoS One. 2013 Apr 18;**8**(4):e61466. DOI: 10.1371/journal.pone.0061466

[42] Tremellen K, McPhee N, Pearce K, Benson S, Schedlowski M, Engler H. Endotoxin-initiated inflammation reduces testosterone production in men of reproductive age. American Journal of Physiology. Endocrinology and Metabolism. 2018 Mar 1;**314**(3):E206-E213. DOI: 10.1152/ ajpendo.00279.2017

[43] Hunt CD, Johnson PE, Herbel J, Mullen LK. Effects of dietary zinc depletion on seminal volume and zinc loss, serum testosterone concentrations, and sperm morphology in young men. The American Journal of Clinical Nutrition. 1992;**56**:148-157

[44] Hamdi SA, Nassif OI, Ardawi MS. Effect of marginal or severe dietary zinc deficiency on testicular development and functions of the rat. Archives of Andrology. 1997;**38**(3):243-253. DOI: 10.3109/01485019708994883

[45] Omu AE, Al-Azemi MK, Al-Maghrebi M, Mathew CT, Omu FE, Kehinde EO, et al. Molecular basis for the effects of zinc deficiency on spermatogenesis: An experimental study in the Sprague-Dawley rat model. Indian Journal of Urology. 2015;**31**(1):57-64. DOI: 10.4103/0970-1591.139570

[46] Hesketh JE. Effects of dietary zinc deficiency on Leydig cell ultrastructure in the boar. Journal of Comparative Pathology. 1982;**92**:239-247

[47] Kambe T, Hashimoto A, Fujimoto S. Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cellular and Molecular Life Sciences. 2014;**71**:3281-3295

[48] Chu Q, Chi Z-H, Zhang X, Liang D, Wang X, Zhao Y, Zhang L, Zhang P. A potential role for zinc transporter 7 in testosterone synthesis in mouse Leydig tumor cells. International Journal of Molecular Medicine 2016, 37(6): 1619-1626. https://doi.org/10.3892/ ijmm.2016.2576

[49] Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proceedings of the National Academy of Sciences of the United States of America. 2004;**101**:4758-4763

[50] Biaggio VS, Alvarez-Olmedo D, Perez Chaca MV, Salvetti NR, Valdez SR, Fanelli MA, et al. Cytoprotective mechanisms in rats lung parenchyma with zinc deprivation. Biometals. 2014;**27**:305-315

#### *Lung Health and Hypoandrogenism DOI: http://dx.doi.org/10.5772/intechopen.108965*

[51] Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nature Reviews. Immunology. 2020;**20**:442-447

[52] Cutolo M, Smith V, Paolino S. Understanding immune effects of estrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination. Clinical and Experimental Rheumatology. 2020;**38**:383-386

[53] Nie X, Qian L, Sun R, et al. Multiorgan proteomic landscape of COVID-19 autopsies. Cell. 2021;**184**:775-791

[54] Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic Proceedings. 2008;**83**:355-367

[55] Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;**75**:2844-2852

[56] Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research. 2016;**5**(3):288-300 DOI: 10.21037/tlcr.2016.06.07

[57] Muscat JE, Stellman SD, Zhang ZF, et al. Cigarette smoking and large cell carcinoma of the lung. Cancer Epidemiology, Biomarkers & Prevention. 1997;**6**:477-480

[58] Chan YX, Alfonso H, Chubb SA, Handelsman DJ, Fegan PG, Hankey GJ, et al. Higher dihydrotestosterone is associated with the incidence of lung cancer in older men. Hormones and Cancer. 2017 Apr;**8**(2):119-126. DOI: 10.1007/s12672-017-0287-4

[59] Harlos C, Musto G, Lambert P, Ahmed R, Pitz MW. Androgen pathway manipulation and survival in patients with lung cancer. Horm Cancer. 2015 Jun;**6**(2-3):120-127. DOI: 10.1007/s12672- 015-0218-1 Epub 2015 Mar 20

[60] Pantazopoulos I, Magounaki K, Kotsiou O, Rouka E, Perlikos F, Kakavas S, et al. Incorporating biomarkers in COPD management: The research keeps going. Journal of Personalized Medicine. 2022 Mar 1;**12**(3):379. DOI: 10.3390/jpm12030379

[61] Antus B. Oxidative stress markers in sputum. Oxidative Medicine and Cellular Longevity. 2016;**2016**:2930434. DOI: 10.1155/2016/2930434

#### **Chapter 6**

## Benefits of Testosterone Replacement and Methods of Substitution

*Kenneth W.K. Ho*

#### **Abstract**

Testosterone substitution and replacement therapy is effective for managing testosterone deficiency. Traditional routes of administration include oral, nasal, transdermal, and intramuscular. Scrotal application of testosterone cream has been made recently available. Physician's choice of one preparation over another is based on testosterone bioavailability, side effect profile and ability to achieve therapeutic levels. Patient's choice is influenced by comfort, ease of use and product acceptability. This is important for compliance and achievement of good outcomes. Testosterone substitution can be overused and associated with adverse effects. Individuals at risk are older, obese with chronic cardiorespiratory disorders, and lower urinary tract symptoms. Therapeutic monitoring is vital and is achieved through measuring serum total testosterone levels and clinical follow-up. Decision on therapy outcomes should be individualised, based on symptom control and testosterone effects on organ function. Supra-therapeutic testosterone levels should be avoided as adverse outcomes such as worsening obstructive sleep apnoea, polycythaemia, and prostatic growth stimulation are more likely.

**Keywords:** routes of administration, monitoring of efficacy, adverse effects, individualised therapy, non-testosterone options

#### **1. Introduction**

In males, testosterone production occurs under the control of the hypothalamicpituitary-testicular (HPT) axis. The gonadotropin pulse generator awakens in the lead up to puberty, driving the development of the testes, with the follicular stimulating hormone (FSH) responsible for the development of the seminiferous tubules and the luteinising hormone (LH), the production of testosterone from testicular Leydig cells. The release of gonadotropins results in enlargement of the testes, and a pair of 4 ml testes signals the start of puberty. The surge in testosterone that follows puberty is responsible for the eventual male phenotype characterised by voice deepening, body hair development, muscular and skeletal growth. Other secondary sexual characteristics include lengthening of the penis, pubic and scrotal hair. Testosterone primes the skeletal response to growth hormone (GH) stimulation and results in the growth spurt that follows puberty. Spermatogenesis arises from FSH stimulating spermatogonia development and spermatozoa production. Testosterone production is regulated

via the hypothalamus-pituitary-testicular axis. Regulation of gonadotropin secretion from the gonadotroph cells in the anterior pituitary occurs through stimulation by gonadotropin-releasing hormone (GnRH) from the hypothalamus. The gonadotroph cells have testosterone (T) and estrogen (E2) receptors that receive negative inhibition from testosterone and oestradiol respectively [1].

Understanding this feedback response pathway allows the clinician to determine the cause of testicular failure. In primary testicular failure, testicular hypofunction results in the fall of testosterone levels and the consequent reduction of feedback inhibition of the hypothalamus and pituitary, result in a corresponding rise of LH and FSH. The causes of testicular hypofunction include destruction of testes through mumps, testicular cancer, alkylating chemotherapeutic agents, and orchidectomies. In secondary testicular failure, disruption of the HPT axis occurs at the hypothalamus and/or pituitary level. Some examples are large sellar tumours that compress on the pituitary, causing irreparable damage to the gonadotroph cells or damage to the pituitary after debulking of large sellar tumours. In such situations, the reduction of LH leads to very low testosterone levels. It is uncommon for direct hypothalamic injury to cause secondary testicular failure. More commonly, secondary testicular failure occurs when supraphysiological doses of testosterone are administered for prolonged periods, resulting in suppression of gonadotropins. When the supraphysiological testosterone doses are stopped, LH and FSH levels remain very low and may take months to recover.

Testosterone has an anabolic effect on cell growth and is important for skeletal and muscular development. Once biosynthesised and released by the testes, testosterone is transported in the blood, bound to sex hormone binding globulin (SHBG) with a small unbound portion (2%), as free testosterone. Around 95% of circulating testosterone reaches the target cells and exerts its effects by entering the cytoplasm and binding to the androgen receptors (ARs). The AR is widely distributed among reproductive and nonreproductive tissues, including the prostate, and seminal vesicles, external genitalia, skin, testes, cartilage, sebaceous glands, hair follicles, sweat glands, cardiac muscle, skeletal muscle and smooth muscle, gastrointestinal vesicular cells, thyroid follicular cells, adrenal cortex, liver, pineal and many cortical and subcortical regions, including spinal motor neurons [2]. The testosterone-AR complex results in rapid cellular signalling cascades via SRC/MAPK/ERK pathways that lead to cell proliferation and survival or enter the nucleus and bind to AR elements on target genes to increase gene expression. About 10% of testosterone is converted to dihydrotestosterone (DHT) via 5 α-reductase activity in the genitals, prostate, and skin. DHT is several times more potent than testosterone and is vital for the sexual differentiation of male genitalia during embryonic development [3]. Approximately 0.1% of testosterone is converted into estrogens by aromatase (CYP19A1) activity in bone, fat, or brain, where testosterone exerts its anabolic activity via the estrogen receptor (ER). All these hormones (testosterone, DHT and estrogens) exert negative feedback on the HPT axis [4].

In men, testosterone levels can vary widely, from very low levels late at night to peak levels in late morning. This is because the pituitary releases LH in a pulsatile manner, dependent upon periods of light and sleep. Normal ranges in healthy eugonadal men vary widely. This may be dependent on ethnic, genetic, and geographical factors. It is also affected by acute and chronic ill health. Total testosterone was determined in a reference sample of 456 healthy young men, (19–40 years), using Liquid Chromatography Tandem Mass Spectrometry, demonstrating that the 2.5 percentile cut-off was 12.1 nmol/l (348.3 ng/dl) and the 97.5 percentile was 41.5 nmol/l

#### *Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

(1196.6 ng/dl). In very healthy men aged 70-89 years, the reference interval using mass spectrometry was 6.4–25.7 nmol/l (184.6-741.2 ng/dL) [5]. Men who describe hypogonadal symptoms but have testosterone levels at the lower limit of the normal eugonadal range, are thought to have functional hypogonadism. They may also have chronic disease or are obese. Clinical testosterone deficiency syndrome, or hypogonadism, refers to a spectrum of symptoms that include physical, psychological, and sexual. Hypogonadal men may report significant fatigue, and muscle weakness, as well as feelings of reduced motivation, and low mood. More commonly, sexual symptoms predominate, such as reduced libido, or disinterest in sexual relations, and poor erections. Hypogonadism is often associated with obesity in a bi-directional causal relationship. Chronically low testosterone levels may predispose to muscle atrophy and fat gain, whilst obesity is thought to exert an inhibitory effect on the gonadotrophs in the anterior pituitary and on the GnRH cells in the hypothalamus. The associations of fatigue with chronically low testosterone are multifactorial and include psychological aspects such as depression and low motivation, but also that of chronic normocytic anaemia, due to reduced erythropoiesis.

When there is clear evidence of primary or secondary testicular dysfunction, i.e., hypogonadal symptoms, associated with persistently low testosterone levels, testosterone replacement or substitution is wholly justified, as hypogonadal symptoms should respond well to intervention. However, where hypogonadal symptoms occur outside these situations, there are differences of opinion as to when testosterone therapy is initiated. An international survey of adult endocrinologists in 2015 indicated that in men with hypogonadal symptoms, 42.4% of endocrinologists surveyed would treat with testosterone replacement [6]. A placebo controlled double blinded randomised controlled trial (RCT) in >65-year-old hypogonadal men with total testosterone level below 9.5 nmol/l (275 ng/dl) showed that raising the total testosterone level to that of mid-normal range for 19–40-year-old men, significantly improved sexual function, and mood, but not vitality or walking distance [7]. Therefore, hypogonadal men with testosterone levels below 9.5 nmol/l (275 ng/dl) may be considered acceptable for testosterone therapy in the absence of correctable lifestyle factors.

#### **2. Effects of testosterone substitution or replacement therapy**

Previous observational studies have suggested that testosterone replacement therapy (TRT) may lead to increased cardiovascular risks, but recent prospective studies have not found this to be so. In contrast these studies have suggested that TRT may be beneficial in reducing the metabolic derangements associated with type 2 diabetes. In a prospective treatment study, 178 such patients with normal baseline testosterone of 12 nmol/l (346.1 ng/dl), were given testosterone undecanoate (TU) and compared with similar patients who did not choose to receive TRT. The TRT group had shown reductions in HbA1c, fasted insulin, fasted glucose levels compared to the matched group who did not receive therapy [8]. Such findings were supported in the recently published T4DM study, which had randomised obese men with the metabolic syndrome to TU depot injection compared to placebo over 6 months and found significant reductions in fasted glucose, reduced abdominal fat mass, and increased muscle mass [9].

Hypogonadal men report reduction in libido and erections, energy, strength and endurance, enjoyment of life, mood, mental concentration, and work performance. TRT is associated with improvement in these areas. The Androgen Deficiency in Ageing Males (ADAM) [10] is a research tool developed by the St. Louis University to assess hypogonadism. The International Index of Erectile Function (IIEF-5) evaluate erectile dysfunction (ED) through measures in erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall sexual function [11]. Studies have shown reduction of ADAM scores and improvement in IIEF-5 scores in hypogonadal men who receive TRT.

Hypogonadal men experience significant changes to their body composition. Administration of androgen deprivation therapy for prostate cancer leads to sustained muscle loss and fat gain, most profound in the first 12 months [12]. The effects can be reversed with testosterone replacement [13], with dual energy X-ray absorptiometry (DEXA) showing reduction in fat mass and increased muscle mass. Loss of lean muscle mass is associated with ageing in men. TRT in men with sarcopenia has been associated with increase in lean muscle mass but the effects on strength and overall quality of life have been inconsistent [14]. Hypogonadal men have a significant risk of secondary osteoporosis [15]. It has been shown that in men who received androgen deprivation therapy, there is increased bone turnover and 2.5% decrease in bone mineral density annually [16]. In a subsequent sub-study of the T4DM, the T4Bone study had shown that TRT may be associated with significantly increased volumetric bone mineral density in cortical bone in obese metabolic men.

Testosterone activates the amygdala enhancing its emotional activity and its resistance to pre-frontal restraining control [17]. Aggressive behaviour arises through interaction between the amygdala and the hypothalamus which brings about emotions which the prefontal cognitive centres then modulate and control. Testosterone is important for psychological maturation of the brain during puberty, which results in anatomical and organisational changes in the male brain. Hypogonadal men often report lack of motivation and often feel low in mood. These symptoms may be due to the physical effects of low testosterone on muscle and bone function. Testosterone replacement can exert profound psychological effects. Testosterone replacement for 51 hypogonadal men (age 22–60 years) with baseline level <8.3 nmol/l (250 ng/dl) over 60 days led to significantly decreases in anger, sadness, irritability, tiredness, nervousness, and improvement in energy, friendliness, and sense of well-being [18]. The levels of testosterone and DHT correlated with improvement on initial treatment, but once therapeutic level was achieved, further escalation of testosterone no longer correlated with improvement.

#### **3. Methods of testosterone substitution**

In ancient times, ingested animal testicular extracts were known to bestow improved vitality and to act as an aphrodisiac [19]. In the early 1900s, injected testicular transplants from goats, ram, deer, boar and bulls were used and even testicles of executed criminals were used to substitute for males with sexual dysfunction [19]. From 1935, synthesis of testosterone from cholesterol became possible and led to the award of the Nobel Prize for Chemistry in 1939 [19]. Testosterone was first trialled as oral administration, but because of extensive first pass metabolism by the liver, it became necessary to alkylate the 17-hydroxy position, giving rise to androgens that are more resistant to hepatic metabolism. 17α-methyl-testosterone was introduced in 1939 by Foss and became extensively used for its androgenic and protein anabolic effects. It can be ingested orally or administered via trans buccal route [20]. After several decades of use however, it was found to cause cholestatic jaundice, reversible hepatotoxicity, and some cases of death, ending its use in the 1980s [21].

#### **3.1 Intramuscular injections**

With the problems encountered from first pass metabolism and hepatotoxicity, other alterations were made to the testosterone molecule to make testosterone administration more effective and safer. Adding an ester moiety to the 17-hydroxy position of synthetic testosterone made it hydrophobic, so it may be stored in oil and injected intramuscularly [22]. Intramuscular injections have been used from early and are currently still one of the most popular modes of administering testosterone. It results in an effective rise in testosterone levels with suppression of gonadotropins, resulting in symptomatic response. Examples are testosterone propionate, testosterone cypionate, testosterone enanthate, and TU. There are significant differences in elimination half-lives, with testosterone propionate being the shortest at 0.8 days, testosterone enanthate 4.5 days, and TU 33.9 days [23]. Testosterone propionate was first used in 1939. Administration of a single dose of 50 mg testosterone propionate led to a supraphysiological peak of 40.2 nmol/l (1159.4 ng/dL) 14 hours later, but quickly returned to below baseline on day 3 (57 hours) after injection, with the troughs between 3-7 nmol/L (86.5-201.9 ng/dL) [24]. Therefore, based on the pharmacokinetics of a single dose, testosterone propionate will have to be injected intramuscularly every 3rd day i.e. twice a week, which would not be practical for long term substitution. In addition, it is associated with peaks as high as 45 nmol/l (1297.9 ng/dL) and troughs of 3 nmol/l (86.5 ng/dL) [23]. It is now administered in a mixture of esters (propionate, phenylpropionate, isocaproate, and decanoate) marketed as Sustanon. However, it became superseded by the longer-acting testosterone enanthate.

Testosterone enanthate was first manufactured in the mid 1950s [25], and is still commonly used, popular among body builders. Snyder et al [26]. tested the efficacy of testosterone enanthate for treating male primary hypogonadism and determined that the regimens most practical in terms of injection interval and yet effective in suppressing LH to normal levels, were 200 mg every 2 weeks or 300 mg every 3 weeks. Salmimies et al administered fortnightly injections of testosterone enanthate in a range of doses from 50 to 250 mg, to hypogonadal males with a variety of aetiologies such as testicular, pituitary, or hypothalamic failure. They documented their sexual behaviour via questionnaires. In general, improvements in sexual desire, erectile frequencies and ejaculations were dose dependent. However, the treatment threshold below which hypogonadal symptoms were to occur was wide, from 6.9 nmol/l (200 ng/dL) to 15.6 nmol/l (450 ng/dL) [27]. Testosterone cypionate has a similar pharmacokinetic profile to testosterone enanthate. Intramuscular injection of 200 mg testosterone cypionate leads to a peak of 38.5 + 15.3 nmol/l (1108 + 440 ng/dl) from 2 to 3 days and progressively decline from day 5 to pre-injection baseline at 14 days [28]. There is a corresponding peak and decline in free testosterone and oestradiol levels. The frequency of injections every 2–3 weeks for both testosterone esters and the wide testosterone fluctuations makes it less than ideal for long term use.

TU was synthesised in the 1970s by adding the undecyclic acid to the C17β position of testosterone. When administered orally, it is absorbed via gut lymphatics and therefore by-passes the liver. After reaching the blood circulation, it undergoes de-esterification, releasing the unmodified testosterone [29]. It was first used orally and provided a safe non-injected method of administering testosterone that bypassed the liver and circumvented the issues of liver toxicity [30]. In 1980s, the World Health Organisation sponsored a Special Programme of Research, Development and Research Training in Human Reproduction which developed an injectable TU prepared in tea seed oil and introduced in the late 1990s. When administered as a

500 or 1000 mg dose, it resulted in a peak of 47.8 + 10.1 nmol/l (1379 + 291 ng/dL) and 54.2 + 4.8 nmol/l (1563 + 138 ng/dL) at the end of 7 days and declined to baseline by 6–8 weeks, showing an elimination half-life of 18.3 + 2.3 days and 23.7 + 2.7 days respectively [31]. It was first trialled in China with repeated 500 mg in 4 ml injections every 6–8 weeks. A newer more concentrated formulation was later developed by Jenapharm/Schering, in which 1000 mg of TU was completely dissolved in benzyl benzoate, diluted in 4 ml of refined castor oil and delivered in a vial [32].

In the initial pharmacokinetics studies carried out at Munster, Germany, a single injection of 1000 mg of TU resulted in peak testosterone level of 22.2 + 2.0 nmol/l (640 + 57.7 ng/dL) at 7–14 days, with levels >10 nmol/l (288 ng/dL) for up to 8 weeks. When 1000 mg was given every 6 weeks for 5 months, there was steady accumulation of testosterone to 40.8 + 3.8 mmol/l (1177 + 109.6 ng/dL) at 6 months. There was a significant slow and steady rise of DHT and oestradiol levels and slight decline in SHBG levels. FSH and LH were suppressed at the end of the 6-month study. There was a significant slight increase in prostate volume, but it remained low [33]. Therefore, the optimal regimen of administrating TU is to give the first two injections 6 weeks apart and thereafter, the injection interval could be 10–14 weeks depending on the trough testosterone levels [32, 33]. It was first marketed at the end of 2003 in Europe, Latin America, and in Asia as Nebido (Bayer) and in Spain and Australia as Reandron 1000 (Bayer). It is available in a 4 ml vial with a concentration of 250 mg/ml formulation. Another TU injectable formulation Aveed (Endo Pharmaceuticals Solutions Inc.) was launched in the USA in 2010 as a single 3 ml ampoule containing 750 mg of TU. The 3 ml injection was given at baseline, 4 weeks later and then maintained at 10 weeks intervals. During a multicentre US based study the on-treatment troughs through a 64 week duration ranged from 10.8 to 13.5 nmol/l (309.6–389.8 ng/dl), and free testosterone, SHBG, DHT and oestradiol remained constant, while LH and FSH were suppressed [34].

#### **3.2 Testosterone implants**

Subdermal implant techniques were originally developed in the late 1930s and were first used to deliver testosterone pellets made up of compressed testosterone and cholesterol in the early 1950s. It has been in clinical use for >50 years, but its popularity waxed and waned during the 1980s into the 21st century. The technique and follow up procedures have been well described by Handelsman et al [35]. Implants are administered under sterile conditions by an experienced operator with an assistant, in a routine office setting using stainless steel wide-bore trocar (7.5 French gauge, 5 mm ID, 7 cm length), cannula and obturator set. Implants are placed subdermally in the lower abdominal wall lateral to or just about the level of the umbilicus. The supine patient's abdominal skin is prepped anti-septically and draped. Following a local anaesthetic injection, a small incision is made (0.5–1.0 cm) at least 5 cm from the midline, to allow introduction of the trocar. This permits the insertion of four 200 mg testosterone pellets radiating subdermally from the initial incision site, expelled from the trocar by the obturator at 5–10 cm from the puncture site. The puncture wound is closed without suture using adhesive sterile strips and covered by a clear, waterproof adhesive dressing, left in place for 5–7 days and removed by the patient. Subsequent implantations are usually scheduled every 4–6 months, but patients are generally reviewed in-between with or without testosterone levels. Most patients have no side effects and there is a high continuation rate of >90% over a decade. Main adverse events are minor infections, and oozing or minor bleeding, and extrusion of pellets as a result. The risk predictors for adverse events are increased physical activity at work,

#### *Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

number of pellets inserted, and thinness of patients, who make the technique more difficult because of reduced subcutaneous fat.

Jockenhovel studied the pharmacokinetics of a single subdermal implantation of T-pellets in 14 hypogonadal men with baseline testosterone level below 3.6 nmol/l (103.8 ng/dL) [36]. Following implantation, there was a rapid rise of testosterone level to about 49 nmol/l (1413.3 ng/dL) within 2 days, followed by a plateau phase for a month, and a gradual decline to baseline by 12 months. Mean serum testosterone was below 10 nmol/l (288.4 ng/dL), after 6 months. Rise in serum DHT correlated with the initial rise of serum testosterone levels, but the DHT/testosterone ratio decreased after the implantation and was significantly below baseline from day 21 to 189. SHBG demonstrated a rapid decline in response to T-pellets but returned to baseline by day 300. Both LH and FSH were rapidly and markedly suppressed by testosterone pellet implantation, recovering towards their baseline by 6 months. Again, the adverse events are low, and relatively minor, and most men are happy to continue. A potential disadvantage is the rapid and extreme peak of testosterone after implantation and its implications on prostate growth. The other consideration is a degree of training and experience is needed for the procedure. However, the pellets are relatively inexpensive.

#### **3.3 Oral administration**

Current versions are available as TU administered in softgel capsules. There are several trade names, Andriol, Jatenza, and Tlando. Clinical studies have suggested oral preparations to be effective. Serum testosterone levels have increased by more than 50% after several months of daily use. This was associated with improvement in ADAM questionnaire scores and AMS scale, but not SF-36 scale [37]. Oral TU rely on absorption via gut lymphatics and should be administered twice or thrice with meal, preferably with some fat content. Gut absorption can therefore be subjective and contributes to testosterone level fluctuations. However, it is generally a safe option for use in older men, especially if prostate specific antigen (PSA) needs to be carefully followed.

Other oral preparations include administration of 30 mg testosterone via a sustained and controlled transbuccal route [38]. This involves the application of a small tablet pressed firmly onto the gums of the upper incisors for about 30 seconds, twice daily. The adhered tablet absorbs saliva to form a gel and is subsequently absorbed into the mucosa. It leads to a steady rise of testosterone levels to between 10 nmol/L (288.4 ng/dL) and 20 nmol/l (576.8 ng/dL). Upon cessation of therapy, baseline levels are returned after 14 days. Adherence to therapy is reasonably good, with >60% compliance. However, it is not a popular mode of replacement and is not widely available in many countries except in North America. Common issues are gum mucosa irritation.

#### **3.4 Transdermal applications**

There are several methods whereby testosterone can be administered topically. These can be done transdermally via scrotal (Testoderm), or non-scrotal skin patches (Androderm) or by transdermal hydroalcoholic gel (AndroGel or Testogel), or by creams (AndroForte). Transdermal patches were first used on the scrotal skin in 1987 [39]. It was a logical choice as the scrotal skin has the thinnest stratum corneum, which would allow easy penetration. However subsequent issues with poor

adhesiveness, and the need for regular shaving and excessive DHT levels, made it an unpopular choice among clinicians and patients. Non-scrotal patches were trialled [40–42], and but required an effective alcohol-based excipient to allow adequate permeation of the testosterone through the thicker stratum corneum. This resulted in frequent skin irritation and often burn-like reactions [43]. It too fell out of favour.

In 2010, the FDA had approved a unique product containing 2% *w*/*v* testosterone dissolved in a solvent mixture of ethanol and isopropanol. The testosterone solution was provided in a bottle with a metered dose pump and a detachable applicator. A metered dose delivers 1.5 ml (equivalent to 30 mg of testosterone) into the applicator, which the patient then uses to rub the solution onto the axilla, and then allow the solution to evaporate after 3 minutes. The procedure is then repeated on the other axilla. The testosterone solution also contains octisalate which aids in the permeability of transdermal testosterone. This product was effective in restoring total testosterone levels to the normal range after 15 days in most individuals, with improvement in hypogonadal symptoms, through two metered doses (60 mg) daily [44]. The men were instructed to avoid having their partners or children touch their axillary areas as traces of testosterone can be recovered after application. However, for unspecified reasons, this product was removed from the market in 2017.

Testosterone transdermal gels were introduced in the early 2000s. Over the last 10 years, the product was marketed as a hydroalcoholic gel containing 1% (10 mg/g) of testosterone, delivered via metered actuations each containing 12.5 mg of testosterone. The standard daily dose was four to eight actuations (50–100 mg), with the starting dose at 50 mg, and increased as needed in consultation with their doctors, up to 100 mg daily. Bodily sites where the patients could apply the gel include the shoulders, upper arms, chest, and upper torso areas. The gel was applied in the morning, after a shower if needed, and the applied areas allowed to dry thoroughly (within minutes) and covered with clothing appropriately to prevent inadvertent transference to others. Testosterone levels were elevated into the eugonadal range with appropriate suppression of gonadotropins and was associated with improvements in mood, sexual function, satisfaction, and body composition. Adverse events were acceptably low, at 5.5%, and were mainly from mild skin erythema [43]. Testogel has been a highly marketed product and enjoys popularity world-wide.

Testosterone is also available as a 5% (50 mg/ml) alcohol-free topical testosterone cream (AndroForte 5). The T cream was supplied with a dose measuring applicator graduated in 0.5 ml increments. Patients can start with 2 ml (100 mg) with a maximum dose of 4 ml (200 mg) of cream massaged evenly over the skin of the torso daily. The dose can be adjusted over 3 months with consultation of their doctors. The treatment is effective in raising testosterone levels into the eugonadal range with appropriate lowering of gonadotropins. It is comparable to the use of Testogel with no difference in adverse events between the two products [45]. AndroForte 5 may also be administered as a scrotal skin application. Iyer et al. have shown effective elevation of testosterone levels with just a low dose of 12.5 mg (0.25 ml) and is comparable to that of 100 mg (2 ml) applied onto the abdominal skin [46]. This suggests that an eightfold increase in bioavailability is attained via the scrotal skin route, which as discussed, has a thin stratum corneum and also has a high concentration of 5α reductase levels, which converts testosterone to DHT levels. Patients generally start with 0.5 ml (25 mg) massaged into the scrotum daily. There is no need to remove scrotal hair as the cream is well absorbed into the scrotum. The daily dose can be increased by 0.25 ml up to 0.75 ml if needed over 3–6 months in consultation with medical practitioners. This therefore provides an economical yet effective way of testosterone substitution.

#### **3.5 Nasal delivery**

Another method of delivery that has been generally available in North America since 2015 is that of nasal testosterone gel. Natesto is a 4.5% testosterone thixotropic gel applied intranasally by delivering 5.5 mg via a metered dose pump, into each nostril two or three times a day. In an open-label dose titration study, that included overweight men (mean age 54 years) with late-onset (functional) hypogonadism, 306 were randomly assigned to either twice or thrice daily regimens [47]. Patient responses were quantified using the IIEF and the Positive and Negative Effect Schedule (PANAS) at baseline and at 30-day intervals for 3 months. Regardless of the baseline total testosterone levels, which can range from <3.4 nmol/l (<100 ng/ dl) to 27.3 nmol/l (800 ng/dl), administration of Natesto led to a rapid rise of total testosterone to about 24.4–27.3 nmol/l (700–800 ng/dl) after an hour but returns to baseline after 6 hours. At day 90 of treatment, there were corresponding rises in IIEF scores of about 40%, irrespective of the baseline pre-treatment total testosterone levels and an increase in positive PANAS and decrease in negative PANAS scores. In a dose titration study, patients were started with a divided daily dose of 22 mg but may be titrated to 33 mg depending on symptoms at day 90. The majority stayed on 22 mg daily, whilst a third of patients preferred the 33 mg daily dose [48]. Symptoms were recorded using the qADAM, and patient satisfaction was documented at baseline, and at 30 day intervals up to 120 days. It has been generally well accepted with most citing convenience and ease of use, effectiveness, travel friendliness, but also listing nasal drip as a potential deterrent to using it [48].

#### **4. Testosterone substitution in sports**

Testosterone's potent anabolic effects on musculoskeletal and bone marrow quickly led to widespread illicit use in sports [49, 50]. Testosterone propionate's half-life of 2–3 weeks makes it popular as an ideal anabolic steroid to enhance athletic performance. It became implicated in illicit steroid use and doping scandals in sport use [51]. The advent of mandatory and sophisticated drug testing at international competitions have not eliminated the illicit use of testosterone rather, anabolic steroid use have found themselves into other lesser competitive sporting events such as in high schools and clubs [52]. Individuals have reportedly used testosterone and other anabolic steroids in a pre-specified period leading up to the competition. Giorgi et al have shown that testosterone enanthate administered at supraphysiologic doses at 3.5 mg/kg/week over 12 weeks (approximately 300 mg/week) was associated with improved physical conditioning, doubling of muscle strength and increased weight over placebo. However, upon withdrawal of testosterone injections, the enhancements did not continue, and subjects would return to their baseline 12 weeks after cessation, despite ongoing training [53]. Concerningly, youths are turning to anabolic steroids to enhance not only their physical performance but also their physical appearance [54].

#### **5. Opioid induced androgen deficiency**

Individuals who use opioids for long term are at risk of developing hypogonadism [55]. Activation of μ-receptors in the hypothalamic pituitary axis can result in suppression of the gonadal axis. The prevalence of opioid induced androgen deficiency varies

from 19% to 86% depending on the testosterone threshold for defining hypogonadism. The true incidence is likely to be higher than reported as the association is underrecognised by clinicians. The risk is higher in chronic opioid users, with a Morphine Equivalent Dose of greater than 60 mg, but shorter use duration with the more potent and long-acting opioids such as fentanyl are at higher risk. On the hand, opioids with partial μ-receptor agonism such as buprenorphine or tapentadol have lower risks. Affected individuals report sexual dysfunction, depression, reduced fertility, reduced bone health, increased weight, and elevated cardiovascular risks. Testosterone replacement can be achieved via topical or parenteral routes, with benefits in reduction of pain perception, and opioid dosing, improvement in libido, body composition, and bone density.

#### **6. Testosterone for male transgender (transmen) management**

Testosterone is the key hormone for adult individuals with Gender Dysphoria, who want to transition from being a female to male. Transmen who receive testosterone substitution develop amenorrhoea, increased muscle mass and strength, male pattern body hair and deepening of voice. The US Endocrine Society recommends maintaining serum testosterone within the normal male range of 11.1–34.7 nmol/l (320– 1000 ng/dl) [56]. Testosterone substitution methods have included oral, transdermal, and parenteral routes. Pelusi et al [57]. studied testosterone substitution in 45 transmen over a year and randomised them to combined T. propionate/enanthate esters intramuscular injections every 10 days, or daily testosterone gel application or T. undecanoate depot 12 weekly deep intramuscular injections. All three groups report amenorrhoea by the first year of treatment and increased lean mass and reduced fat mass. There were significant changes in lipid profiles without cardiovascular outcomes. All study subjects reported general life satisfaction at 1 year but over time, all of study subjects moved over to maintenance TU treatment. A retrospective 5-year review of 50 transmen between 21 and 42 years of age comparing T undecanoate 1000 mg IMI every 12 weeks with T enanthate 250 mg IMI every 3–4 weeks showed similar results in metabolic and anthropometric parameters. Serum testosterone rose from 1.4 + 0.6 (40.4 + 17.3 ng/dL) to 1.9 + 0.8 nmol/l (54.8 + 23.1 ng/dL) at baseline to range between 12.1 + 3.8 nmol/L (350.0 + 109.6 ng/dL) and 20.8 + 11.4 nmol/l (599.9 + 328.8 ng/dL) over the 5 years. There were consistent reports of improved life satisfaction through attainment of their desired male phenotype. Though there were significantly deranged lipid profiles, there are no reports of increased cardiovascular mortality in transmen within two decades of therapy [58].

#### **7. Testosterone substitution pitfalls and monitoring requirements**

With improved testosterone assays, the challenge of testosterone therapy is to find substitution routes that not only ensure a consistent testosterone delivery but also allow safe therapeutic monitoring and prevent transference to others. Currently the options are oral administration via the oro-gastric route, trans-buccal, transdermal gels, transdermal patches, deep intramuscular injections, and subcutaneous dermal implants. WHO recommendations for the ideal TRT preparation are that it must be safe, effective in correcting symptoms and consequences of T deficiency, inexpensive, of easy administration, with good release profile, ensuring reproducible circulating levels of T and prolonged duration of action, flexible dosing and able to maintain

#### *Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

normal physiologic levels of testosterone. Side effects relate to the excessive peaks and troughs. They include acne, injection pain, and nerve injury. Other unintended consequences are potentially reducing male fertility, worsening sleep apnoea, increased haematocrit and precipitation of polycythaemia, prostatic hyperplasia, un-masking of undiagnosed prostatic cancer and breast cancer, the rare pulmonary oil microembolism (POME), and anaphylaxis.

Careful attention should be given to older men, those with prostate hypertrophy, obese men who are at risk of sleep apnoea, or unstable coronary artery disease. Testosterone therapy may unmask sleep apnoea, and if untreated, may precipitate polycythaemia. It is recommended to keep haematocrit <54%. Prostatic hyperplasia during testosterone therapy is usually not a problem if done carefully. It is prudent to start with short-acting preparations such as testosterone gels or short-acting testosterone enanthate in men with moderate risk. Consider digital rectal examination in at-risk men, for example those with family history of prostate cancer, between 55 and 69 years of age. PSA must be measured at baseline, prior to starting and 6 monthly during TRT. However, after initial 12 months of documented safety, PSA may be monitored once every 12 months. Younger or pre-pubertal males are particularly sensitive to the psychological and sexualising effects of testosterone, so it is prudent to start with low doses and to increase slowly [59]. Testosterone therapy is also contraindicated in males with hepatocyte tumours because of its stimulatory effects on Cyclin E kinase activity potentially driving carcinogenesis [60].

Patients should be counselled on the risks versus benefits of testosterone therapy. Testosterone therapy can be done effectively and safely. The various options are discussed with the patient, and the most suitable route of administration decided, based on the effectiveness, safety of monitoring, drug access, cost, and patient acceptability. Patients should be reviewed at 3–6 monthly intervals. Assessment of efficacy and side effects along with therapeutic monitoring should be done at each visit. This involves assessing testosterone levels, LH, FSH, and PSA levels. Testosterone levels often correlate with symptom improvement, but maintenance of low normal trough testosterone levels maybe important for prevention of over treatment and drug toxicity. It is particularly pertinent in long acting (depot) preparations such as intramuscular TU.

#### **8. Non-testosterone substitution options**

#### **8.1 Tribulus terrestris**

Non-testosterone herbal extracts may have a role in treating ED and male hypoactive sexual desire disorder (HSDD). Tribulus terrestris or commonly known as Puncture Vine, have been used for thousands of years in Asiatic cultures as an aphrodisiac. The plant contains steroidal saponins, flavonoids, flavanol glycosides, alkaloids, and tannins in varying quantities and proportions. These chemicals are thought to be physiologically active and are used in traditional communities for their medicinal properties. Mechanisms of action are not well understood, and may be mediated by changes in hormones, cytokines, and growth factors release, binding and action [61]. It may induce relaxation of the corpus cavernosum and therefore improve erectile function. It is proposed that saponins like dioscine, diosgenin, and protodioscin can have beneficial effects on libido [62].

Few studies have properly assessed the role of Tribulus terrestris in treating ED and HSDD in men, amid anecdotal claims of varying efficacy. A randomised double-blind, placebo-controlled trial was reported in 2016 across multiple sites in Bulgaria [63]. Patients were recruited from andrology, endocrinology and urology clinics and included males with ages >18 and <65 years, with mild to moderate ED, as defined by the IEFF score. Excluded patients were those with severe ED, spinal cord injury, primary HSDD, hyperprolactinaemia < two times upper limit, total testosterone < 8 mmol/l (230.7 ng/dl), uncontrolled major psychiatric disorders, chronic alcohol overuse, poorly controlled diabetes with HbA1c >7.0%, hypertension, unstable cardiovascular disease, stage 4 chronic kidney disease, elevated liver function tests > three times upper limit normal, prostate hypertrophy or cancer, or receiving androgen treatment. 180 patients were randomised to active group or a placebo-matched group. The active drug contained two tablets (500 mg) Tribestan administered orally three times daily after meals for 12 weeks. Tribestan (Sopharma AD) is a herbal medicinal product of Bulgaria origin, standardised with respect to furostanol saponins, calculated against protodioscin. Each tablet contains the active substance TT herba extractum siccum (35–45:1) 250 mg. The control group received identical tablet in colour and taste.

Patients were monitored monthly, with their sexual function assessed by the IIEF psychometric tool and the Global Efficacy Question (GEQ ) log. Blood testing were performed at the start and end of the study and adverse events were carefully noted throughout and post study. The study showed that patients receiving Tribulus terrestris reported higher IIEF scores 2.70 OR (1.40–4.01) CI, and GEQ 4.55 OR (2.35–8.93) CI. These patients reported significantly improved erectile function, intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction. Over the course of treatment, patients receiving Tribulus terrestris did not exhibit differences in lipids, blood pressure, hormones such as total testosterone, free testosterone, SHBG, and dehydroepiandrosterone sulphate (DHEAS). Therefore, individuals with mild to moderate ED, may benefit from Tribulus terrestris without significant changes in lipids, and BP.

#### **8.2 Selective androgen receptor modulators**

As mentioned, testosterone exerts its main actions by binding to the AR, triggering important cellular signalling processes and gene transcriptions. It also has important secondary effects via aromatisation to estrogens, impacting on androgenic alopecia, bone re-modelling and by converting to DHT via 5α-reductase, exerting potent stimulatory effects on prostate growth. Since the 1990s, the concept of Selective Androgen Receptor Modulators (SARMs) as molecules that selectively activate ARs in targeted tissues without aromatisation to estrogens or undergoing 5α-reductase conversion to DHT is appealing [64]. SARMs can be engineered to specifically target AR in certain tissues while minimizing off-target effects. For example, SARMs would activate AR in muscle and bone, whilst sparing other tissues such as prostate, heart and liver. There is minimal variation in the AR structure, but the regulatory milieu of each tissue allows SARMs to possess relative tissue specificity. Upon entering the cell, SARMs bind to the AR in the cytosol, which dissociates from heat shock proteins and enters the nucleus, where the ligand-AR complex then binds with AR responsive peptides (co-activators or co-repressors) specific to certain tissues. This will influence how the SARM-AR complex may bind specific DNA sequences and lead to transcriptional regulation of androgen-responsive genes. Several experimental SARMs were available since 1998, with pre-clinical studies demonstrating positive effects on osteoporosis, cancer cachexia, and detrusor urinary incontinence. However, to date, they have not demonstrated enough efficacy or safety to pass the

clinical trials [64]. Therefore at present, SARMs cannot be a substitute for managing androgen deficiency.

#### **8.3 Estrogen antagonism**

As mentioned afore, regulation of gonadotropin secretion occurs through stimulation by GnRH from the hypothalamus, and negative inhibition of the gonadotroph cells from testosterone and estrogens respectively. Selective Estrogen Receptor Modulators (SERM) work by selectively antagonising E2 receptors on the gonadotroph cells, abolishing the inhibition on gonadotropin release, and therefore elevate gonadotropins and testosterone levels. Likewise, by preventing the conversion of testosterone to oestradiol, aromatase inhibitors (AIs) block the inhibitory effect of oestradiol on hypothalamus and pituitary, thereby increasing LH-stimulated testosterone production. Estrogen antagonism is effective in normalising testosterone levels in men with functional hypogonadism [65–70], and both SERMs and AIs increase the testosterone/estrogen ratio with the latter, significantly more so.

The use of clomiphene citrate a SERM, was studied in obese males (<40 years) with total testosterone 10.4 nmol/l (<300 ng/dl) in a randomised double-blind placebo-controlled trial over 12 weeks. That showed positive findings with significantly improved erectile function, lean and muscle mass [71]. Use of SERMs may have beneficial effects on male fertility. Obese men aged 18–60 years with functional hypogonadism were randomised to receive enclomiphene, testosterone gel or placebo in a randomised double-blind double-dummy placebo-controlled trial over 16 weeks. Enclomiphene is a trans-isomer of clomiphene with consistent estrogen antagonism. As expected, there is a similar doubling of total testosterone levels in both treatment arms from a baseline of 7.0 nmol/l (203 ng/dl) but elevation of both FSH and LH levels in enclomiphene users and suppression in testosterone gel users. This was associated with a significant 80% increase in sperm concentration in men receiving enclomiphene, whilst the testosterone users showed 50% reduction [72]. An early study also suggested the possible benefit of addition of 400 mg daily vitamin E (an antioxidant) to clomiphene, in an RCT, which resulted in significant near-doubling of sperm counts and resulted in near tripling of pregnancies compared to placebo by 6 months [73].

The effect of anastrozole, a popular AI was compared with testosterone gel and placebo in older (>70 years) overweight men with functional hypogonadism using a 12-month RCT [68]. Both AI and T improved proximal muscle strength but not hand grip strength compared with placebo. Only the T group increased gait speed. There were increases in lean body mass and reduction in fat mass in the intervention groups (AI and T) but they were not statistically significant. An earlier 12-month RCT in 2009 comparing anastrozole and placebo did not observe significantly improved strength or muscle mass in older hypogonadal men receiving anastrozole. However, it may have resulted in improvement in quality of life as there was a documented reduction in ADAM scores, although the statistical significance was not reported [74]. There are variable effects and conflicting reports on sperm count and motility. It is possible that some level of estrogenic activity may be necessary for FSH stimulation and therefore sperm production [75]. Unfortunately, an RCT comparing clomiphene and anastrozole in obese younger males (mean age 32–33 years) failed to find any significance in improved quality of life outcomes using ADAM or IIEF scores, or improved sperm characteristics [70].

Risk of venous thromboembolism (VTE) taking SERMs is 0.12% per year in the normal population but likely at least three times elevated in patients with cancer. The risks of VTE in AIs are considerably less than SERMs and may be similar to that of the general population [70]. However, the overall risk may be increased in the elderly and those with cardiovascular risk factors [76]. Use of anastrozole in older men has been associated with statistically reduced lumbar spine bone density of >80% after 12 months, whilst those on testosterone gel have preserved bone density [68]. SERMs are known to increase bone mineral density [67]. An advantage of estrogen antagonists such as SERMs and AIs is that they tend to be safer in estrogen-sensitive cancers such as hepatocellular, and prostate cancers, and are often used for male breast cancer treatment. Burnett-Bowie et al. found that the PSA levels in older men receiving anastrozole were not different to placebo, despite the substantial increase in testosterone levels. It is possible the reduction of intra-prostate estrogen levels offer protection [74].

#### **9. Conclusion**

Testosterone substitution or replacement therapy is effective for managing testosterone deficiency. Popular routes of administration include oral, transdermal, and intramuscular. Scrotal application of testosterone cream is recently made available. Physician's choice of one preparation over another is based on testosterone bioavailability, side effect profile and ability to achieve therapeutic levels. Patient's choice is influenced by comfort, ease of use and product acceptability. This is important for compliance and achievement of good outcomes. Testosterone replacement can be overused and associated with adverse effects. Individuals at risk are older, obese with chronic cardiorespiratory disorders, and lower urinary tract symptoms. Therapeutic monitoring is vital and is achieved through measuring serum testosterone levels and clinical follow-up. Decision on therapy outcomes should be individualised, based on symptom control and testosterone effects on organ function. Supra-therapeutic testosterone levels should be avoided as adverse outcomes such as worsening obstructive sleep apnoea, polycythaemia, and prostatic growth stimulation are more likely. Assessment of symptomatic improvement is important to justify the risks versus benefits of ongoing testosterone therapy. Dose adjustment should be individualised, accounting for the patients' co-morbidity profile, testosterone levels, haematocrit, and PSA levels. Assessment of osteoporosis with baseline bone mineral density is important, and a progress bone mineral density assessment in 12–24 months may be useful to document benefit or lack thereof. Above all, patients must always be counselled on holistic and self-care management, and include healthy lifestyle measures, such as smoking cessation, and weight management. Non-testosterone substitution options offer alternatives to testosterone therapy, and may have some positive benefit, but are not generally considered as mainstream therapy at the moment.

*Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

#### **Author details**

Kenneth W.K. Ho Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia

\*Address all correspondence to: kenneth.ho@mq.edu.au

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **References**

[1] Hayes FJ, DeCruz S, Seminara SB, Boepple PA, Crowley WF Jr. Differential regulation of gonadotropin secretion by testosterone in the human male: Absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. The Journal of Clinical Endocrinology and Metabolism. 2001;**86**(1):53-58

[2] Negro-Vilar A. Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology and Metabolism. 1999;**84**(10):3459-3462

[3] Pirog EC, Collins DC. Metabolism of dihydrotestosterone in human liver: Importance of 3alpha- and 3betahydroxysteroid dehydrogenase. The Journal of Clinical Endocrinology and Metabolism. 1999;**84**(9):3217-3221

[4] Naamneh Elzenaty R, du Toit T, Fluck CE. Basics of androgen synthesis and action. Best Practice & Research. Clinical Endocrinology & Metabolism. 2022;**101665**

[5] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Norman PE, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. Journal of Clinical Endocrinology and Metabolism. 2012;**97**(11):4030-4039

[6] Grossmann M, Anawalt BD, Wu FC. Clinical practice patterns in the assessment and management of low testosterone in men: An international survey of endocrinologists. Clinical Endocrinology. 2015;**82**(2):234-241

[7] Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. The New England Journal of Medicine. 2016;**374**(7):611-624

[8] Haider KS, Haider A, Saad F, Doros G, Hanefeld M, Dhindsa S, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes, Obesity & Metabolism. 2020;**22**(11):2055-2068

[9] Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): A randomised, double-blind, placebocontrolled, 2-year, phase 3b trial. Lancet Diabetes and Endocrinology. 2021;**9**(1):32-45

[10] Mohamed O, Freundlich RE, Dakik HK, Grober ED, Najari B, Lipshultz LI, et al. The quantitative ADAM questionnaire: A new tool in quantifying the severity of hypogonadism. International Journal of Impotence Research. 2010;**22**(1):20-24

[11] Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International Journal of Impotence Research. 1999;**11**(6):319-326

[12] van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer:

*Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

A 2-year prospective study. Critical Reviews in Oncology/Hematology. 2008;**68**(2):172-177

[13] Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. Journal of Clinical Endocrinology and Metabolism. 1996;**81**(12):4358-4365

[14] Huang LT, Wang JH. The therapeutic intervention of sex steroid hormones for sarcopenia. Frontiers in Medicine. 2021;**8**:739251

[15] Ebeling PR. Clinical practice. Osteoporosis in men. The New England Journal of Medicine. 2008;**358**(14):1474-1482

[16] Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism. 2005;**90**(12):6410-6417

[17] Batrinos ML. Testosterone and aggressive behavior in man. International Journal of Endocrinology and Metabolism. 2012;**10**(3):563-568

[18] Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. Journal of Clinical Endocrinology and Metabolism. 1996;**81**(10):3578-3583

[19] Hoberman JM, Yesalis CE. The history of synthetic testosterone. Scientific American. 1995;**272**(2):76-81

[20] Foss GL. A comparison of the relative efficacy of methyltestosterone by the gastric and oral transmucosal routes. Journal of Endocrinology. 1956;**13**(3):269-273

[21] Foss GL, Simpson SL. Oral methyltestosterone and jaundice. British Medical Journal. 1959;**1**(5117):259-263

[22] Bagatell CJ, Bremner WJ. Androgens in men – uses and abuses. The New England Journal of Medicine. 1996;**334**(11):707-714

[23] Behre HM, Nieschlag E. Testosterone preparations for clinical use in males. In: Nieschlag E, Behre HM, Nieschlag S, editors. Testosterone: Action, Deficiency, Substitution. 4th ed. United Kingdom: Cambridge University Press; 2012. pp. 309-335

[24] Nieschlag E, Cuppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Hormone Research. 1976;**7**(3):138-145

[25] Nieschlag E, Nieschlag S. Testosterone deficiency: a historical perspective. Asian Journal of Andrology. 2014;**16**(2):161-168

[26] Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology and Metabolism. 1980;**51**(6):1335-1339

[27] Salmimies P, Kockott G, Pirke KM, Vogt HJ, Schill WB. Effects of testosterone replacement on sexual behavior in hypogonadal men. Archives of Sexual Behavior. 1982;**11**(4):345-353

[28] Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertility and Sterility. 1987;**47**(6):1004-1009

[29] Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: A double blind controlled study. Clinical Endocrinology. 1981;**14**(1):49-61

[30] Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klinische Wochenschrift. 1976;**54**(18):875-879

[31] Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Journal of Andrology. 1998;**19**(6):761-768

[32] Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opinion on Pharmacotherapy. 2014;**15**(13):1903-1926

[33] Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clinical Endocrinology. 1999;**51**(6):757-763

[34] Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. Journal of Andrology. 2010;**31**(5):457-465

[35] Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. Clinical Endocrinology. 1997;**47**(3):311-316

[36] Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and

pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clinical Endocrinology. 1996;**45**(1):61-71

[37] Jungwirth A, Plas E, Geurts P. Clinical experience with Andriol Testocaps – the first Austrian surveillance study on the treatment of late-onset hypogonadism. The Aging Male. 2007;**10**(4):183-187

[38] Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: Pharmacokinetics study in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 2004;**89**(8):3821-3829

[39] Findlay JC, Place VA, Snyder PJ. Transdermal delivery of testosterone. Journal of Clinical Endocrinology and Metabolism. 1987;**64**(2):266-268

[40] Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 1992;**74**(3):623-628

[41] Yu Z, Gupta SK, Hwang SS, Cook DM, Duckett MJ, Atkinson LE. Transdermal testosterone administration in hypogonadal men: Comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. Journal of Clinical Pharmacology. 1997;**37**(12):1129-1138

[42] Yu Z, Gupta SK, Hwang SS, Kipnes MS, Mooradian AD, Snyder PJ, et al. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal

*Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

men. Journal of Clinical Pharmacology. 1997;**37**(12):1139-1145

[43] Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 2000;**85**(8):2839-2853

[44] Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgendeficient men. Clinical Endocrinology. 2011;**75**(6):836-843

[45] Wittert GA, Harrison RW, Buckley MJ, Wlodarczyk J. An openlabel, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101. Andrology. 2016;**4**(1):41-45

[46] Iyer R, Mok SF, Savkovic S, Turner L, Fraser G, Desai R, et al. Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology. 2017;**5**(4):725-731

[47] Gronski MA, Grober ED, Gottesman IS, Ormsby RW, Bryson N. Efficacy of nasal testosterone gel (Natesto®) stratified by baseline endogenous testosterone levels. Journal of the Endocrine Society. 2019;**3**(9):1652-1662

[48] Lee J, Brock G, Barkin J, Bryson N, Gronski MA, Ormsby R. The My-T study: patient satisfaction and preference comparing topical and nasal testosterone therapies. Canadian Urological Association Journal. 2019:384-389

[49] Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism. 1980;**29**(12):1278-1295

[50] Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. International Journal of Andrology. 1988;**11**(4):247-264

[51] Yesalis CE, Anderson WA, Buckley WE, Wright JE. Incidence of the nonmedical use of anabolic-androgenic steroids. NIDA Research Monograph. 1990;**102**:97-112

[52] Wood RI, Stanton SJ. Testosterone and sport: Current perspectives. Hormones and Behavior. 2012;**61**(1):147-155

[53] Giorgi A, Weatherby RP, Murphy PW. Muscular strength, body composition and health responses to the use of testosterone enanthate: A double blind study. Journal of Science and Medicine in Sport. 1999;**2**(4):341-355

[54] Buckley WE, Yesalis CE 3rd, Friedl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. Journal of the American Medical Association. 1988;**260**(23):3441-3445

[55] Ho KWK. Opioid-induced androgen deficiency (OPIAD): Prevalence, consequence, and efficacy of testosterone replacement. Current Opin in Endo and Metab Res. 2019;**6**:54-59

[56] Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. Journal of Clinical

Endocrinology and Metabolism. 2017;**102**(11):3869-3903

[57] Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, et al. Effects of three different testosterone formulations in femaleto-male transsexual persons. Journal of Sexual Medicine. 2014;**11**(12):3002-3011

[58] Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology. 2011;**164**(4):635-642

[59] Stancampiano MR, Lucas-Herald AK, Russo G, Rogol AD, Ahmed SF. Testosterone therapy in adolescent boys: The need for a structured approach. Hormone Research in Pædiatrics. 2019;**92**(4):215-228

[60] Pok S, Barn VA, Wong HJ, Blackburn AC, Board P, Farrell GC, et al. Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology. 2016;**31**(6):1210-1219

[61] Sirotkin AV, Kolesarova A. Puncture vine (*Tribulus terrestris* L.) in control of health and reproduction. Physiological Research. 2021;**70**(Suppl4):S657-SS67

[62] Sellami M, Slimeni O, Pokrywka A, Kuvacic G, Hayes LD, Milic M, et al. Herbal medicine for sports: A review. Journal of the International Society of Sports Nutrition. 2018;**15**:14

[63] Kamenov Z, Fileva S, Kalinov K, Jannini EA. Evaluation of the efficacy and safety of *Tribulus terrestris* in male sexual dysfunction - a prospective, randomized, double-blind, placebo-controlled clinical trial. Maturitas. 2017;**99**:20-26

[64] Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Molecular and Cellular Endocrinology. 2018;**465**:134-142

[65] Patel DP, Brant WO, Myers JB, Presson AP, Johnstone EB, Dorais JA, et al. The safety and efficacy of clomiphene citrate in hypoandrogenic and subfertile men. International Journal of Impotence Research. 2015;**27**(6):221-224

[66] Pelusi C, Giagulli VA, Baccini M, Fanelli F, Mezzullo M, Fazzini A, et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLoS One. 2017;**12**(9):e0183369

[67] Wong SK, Mohamad NV, Jayusman PA, Shuid AN, Ima-Nirwana S, Chin KY. The use of selective estrogen receptor modulators on bone health in men. The Aging Male. 2019;**22**(2):89-101

[68] Awouters M, Vanderschueren D, Antonio L. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Andrology. 2020;**8**(6):1590-1597

[69] Dias JP, Melvin D, Simonsick EM, Carlson O, Shardell MD, Ferrucci L, et al. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial. Andrology. 2016;**4**(1):33-40

[70] Helo S, Ellen J, Mechlin C, Feustel P, Grossman M, Ditkoff E, et al. A randomized prospective double-blind comparison trial of clomiphene citrate

*Benefits of Testosterone Replacement and Methods of Substitution DOI: http://dx.doi.org/10.5772/intechopen.109345*

and anastrozole in raising testosterone in hypogonadal infertile men. Journal of Sexual Medicine. 2015;**12**(8):1761-1769

[71] Soares AH, Horie NC, Chiang LAP, Caramelli B, Matheus MG, Campos AH, et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: A randomized, double-blind, placebocontrolled study. International Journal of Obesity. 2018;**42**(5):953-963

[72] Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU International. 2016;**117**(4):677-685

[73] Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: A randomized controlled trial. Fertility and Sterility. 2010;**93**(7):2232-2235

[74] Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: A randomized, doubleblind, placebo-controlled trial. Clinical Endocrinology. 2009;**70**(1):116-123

[75] O'Donnell L, Robertson KM, Jones ME, Simpson ER. Estrogen and spermatogenesis. Endocrine Reviews. 2001;**22**(3):289-318

[76] Lycette JL, Luoh SW, Beer TM, Deloughery TG. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature. Breast Cancer Research and Treatment. 2006;**99**(3):249-255

## *Edited by Hirokazu Doi*

Testosterone regulates the physiological functions and morphology of biological organisms including humans at multiple stages of development. Understanding what is currently known about testosterone is important for specialists in many branches of science, including internal medicine, veterinary medicine, sports science, economics, cognitive neuroscience, and psychology. This book describes what is currently known about the androgenic function and its underlying mechanisms as well as reviews ethical and safety issues surrounding the clinical and practical application of achievements in testosterone research.

Published in London, UK © 2023 IntechOpen © Staras / iStock

Testosterone - Functions, Uses, Deficiencies, and Substitution

Testosterone

Functions, Uses, Deficiencies, and Substitution

*Edited by Hirokazu Doi*